** Shares of cosmetic drugmaker Evolus EOLS.O rise 3.7% to $14.88 in extended trade
** Co reports adjusted income of $6.7 million in Q4, compared with a year-ago loss of $3.7 million
** EOLS sees 2025 rev between $345 million and $355 million, versus Wall Street estimates of $351.3 million — LSEG
** Co says annual net revenue can reach at least $700 million by 2028
** EOLS rose 4.8% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com))